Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery.
Abstract Hyperlipidemia is a major risk factor for cardiovascular disease, highlighting the need for safer and effective therapeutic options. This study evaluated the anti-hyperlipidemic potential of taxifolin (TXF) and its nanoemulsion formulation (TXF-NE) using integrated computational and experimental approaches. Network pharmacology identified 177 common targets between TXF and hyperlipidemia, with enrichment analyses linking these targets to lipid metabolism, cholesterol regulation, and in...